Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2013 2
2015 1
2017 2
2018 3
2019 1
2020 1
2021 1
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.
Vervoort SJ, Welsh SA, Devlin JR, Barbieri E, Knight DA, Offley S, Bjelosevic S, Costacurta M, Todorovski I, Kearney CJ, Sandow JJ, Fan Z, Blyth B, McLeod V, Vissers JHA, Pavic K, Martin BP, Gregory G, Demosthenous E, Zethoven M, Kong IY, Hawkins ED, Hogg SJ, Kelly MJ, Newbold A, Simpson KJ, Kauko O, Harvey KF, Ohlmeyer M, Westermarck J, Gray N, Gardini A, Johnstone RW. Vervoort SJ, et al. Among authors: kauko o. Cell. 2021 Jun 10;184(12):3143-3162.e32. doi: 10.1016/j.cell.2021.04.022. Epub 2021 May 17. Cell. 2021. PMID: 34004147 Free PMC article.
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J. Kauko O, et al. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. doi: 10.1126/scitranslmed.aaq1093. Sci Transl Med. 2018. PMID: 30021885 Free PMC article.
Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A.
Pavic K, Gupta N, Omella JD, Derua R, Aakula A, Huhtaniemi R, Määttä JA, Höfflin N, Okkeri J, Wang Z, Kauko O, Varjus R, Honkanen H, Abankwa D, Köhn M, Hytönen VP, Xu W, Nilsson J, Page R, Janssens V, Leitner A, Westermarck J. Pavic K, et al. Among authors: kauko o. Nat Commun. 2023 Feb 28;14(1):1143. doi: 10.1038/s41467-023-36693-9. Nat Commun. 2023. PMID: 36854761 Free PMC article.
PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells.
Denisova OV, Merisaari J, Huhtaniemi R, Qiao X, Yetukuri L, Jumppanen M, Kaur A, Pääkkönen M, von Schantz-Fant С, Ohlmeyer M, Wennerberg K, Kauko O, Koch R, Aittokallio T, Taipale M, Westermarck J. Denisova OV, et al. Among authors: kauko o. Mol Oncol. 2023 Sep;17(9):1803-1820. doi: 10.1002/1878-0261.13488. Epub 2023 Jul 26. Mol Oncol. 2023. PMID: 37458534 Free PMC article.
PP2A methylesterase PME-1 suppresses anoikis and is associated with therapy relapse of PTEN-deficient prostate cancers.
Aakula A, Isomursu A, Rupp C, Erickson A, Gupta N, Kauko O, Shah P, Padzik A, Pokharel YR, Kaur A, Li SP, Trotman L, Taimen P, Rannikko A, Lammerding J, Paatero I, Mirtti T, Ivaska J, Westermarck J. Aakula A, et al. Among authors: kauko o. Mol Oncol. 2023 Jun;17(6):1007-1023. doi: 10.1002/1878-0261.13353. Epub 2023 Apr 18. Mol Oncol. 2023. PMID: 36461911 Free PMC article.
Quantitative real-time RT-PCR assay for PCA3.
Väänänen RM, Rissanen M, Kauko O, Junnila S, Väisänen V, Nurmi J, Alanen K, Nurmi M, Pettersson K. Väänänen RM, et al. Among authors: kauko o. Clin Biochem. 2008 Jan;41(1-2):103-8. doi: 10.1016/j.clinbiochem.2007.10.009. Epub 2007 Oct 26. Clin Biochem. 2008. PMID: 17996198
18 results